Thermo Fisher Scientific Inc (NYSE:TMO) Director Jim P. Manzi sold 1,000 shares of the firm’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now directly owns 38,757 shares in the company, valued at $6,790,226.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Thermo Fisher Scientific Inc (TMO) traded down 0.19% on Friday, reaching $172.57. 1,182,702 shares of the company’s stock traded hands. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87. The company has a market cap of $67.32 billion, a PE ratio of 30.06 and a beta of 1.06. The firm’s 50 day moving average price is $176.71 and its 200 day moving average price is $166.56.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.03 earnings per share. On average, equities analysts expect that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/19/thermo-fisher-scientific-inc-tmo-director-jim-p-manzi-sells-1000-shares-of-stock.html.

Several equities research analysts recently issued reports on TMO shares. Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Barclays PLC set a $175.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 26th. Cantor Fitzgerald started coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 18th. They set an “overweight” rating and a $194.00 price target on the stock. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $185.00 price target (up from $175.00) on shares of Thermo Fisher Scientific in a report on Saturday, April 29th. One investment analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $188.56.

Institutional investors have recently made changes to their positions in the stock. DnB Asset Management AS raised its position in shares of Thermo Fisher Scientific by 6.2% in the first quarter. DnB Asset Management AS now owns 85,648 shares of the medical research company’s stock valued at $13,156,000 after buying an additional 5,000 shares in the last quarter. Private Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 9.9% in the first quarter. Private Wealth Partners LLC now owns 85,986 shares of the medical research company’s stock valued at $13,207,000 after buying an additional 7,746 shares in the last quarter. Lodestar Investment Counsel LLC IL raised its position in shares of Thermo Fisher Scientific by 4.4% in the first quarter. Lodestar Investment Counsel LLC IL now owns 70,328 shares of the medical research company’s stock valued at $10,802,000 after buying an additional 2,955 shares in the last quarter. Reilly Financial Advisors LLC raised its position in shares of Thermo Fisher Scientific by 2.3% in the first quarter. Reilly Financial Advisors LLC now owns 59,760 shares of the medical research company’s stock valued at $9,179,000 after buying an additional 1,320 shares in the last quarter. Finally, Washington Trust Bank raised its position in shares of Thermo Fisher Scientific by 0.5% in the first quarter. Washington Trust Bank now owns 2,210 shares of the medical research company’s stock valued at $339,000 after buying an additional 10 shares in the last quarter. 87.60% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.